NasdaqGS:VRTXBiotechs
What Vertex Pharmaceuticals (VRTX)'s IgA Nephropathy Win Means For Its Next Major Franchise Potential
Vertex Pharmaceuticals recently reported that its engineered fusion protein povetacicept met the primary and key secondary endpoints in a Phase 3 RAINIER interim analysis for IgA nephropathy, showing large reductions in urine protein and disease‑related antibodies with a generally manageable safety profile.
The company is moving quickly to complete a rolling Biologics License Application for potential accelerated FDA approval, positioning povetacicept as a possible fourth major franchise...